Steve Worland Worland, PhD

Dr. Steve Worland is currently President and CEO and a director of eFFECTOR Therapeutics (NASDAQ:EFTR), which he co-founded in 2012. Previously, Dr. Worland was CEO of Anadys Pharmaceuticals, a biopharmaceutical company which discovered and developed treatments for hepatitis C and cancer, until its acquisition by Roche in 2011. Prior to being named CEO at Anadys, he was CSO and President, Pharmaceuticals. Dr. Worland began his career at Agouron Pharmaceuticals and remained with the company through its successful commercialization of an HIV protease inhibitor and successive acquisitions by Warner-Lambert and Pfizer. During this period, Dr. Worland held various positions, including Vice President, Director of Molecular Biology and Biochemistry. Dr. Worland was an NIH postdoctoral fellow in molecular biology at Harvard University, received a Ph.D. in chemistry at University of California, Berkeley and a B.S. with Highest Honors in Biological Chemistry from the University of Michigan.